Literature DB >> 11858997

Peptidomimetics of efflux pump inhibitors potentiate the activity of levofloxacin in Pseudomonas aeruginosa.

Thomas E Renau1, Roger Léger, Rose Yen, Miles W She, Eric M Flamme, Joan Sangalang, Carla L Gannon, Suzanne Chamberland, Olga Lomovskaya, Ving J Lee.   

Abstract

Several classes of peptidomimetics of the efflux pump inhibitor D-ornithine-D-homophenylalanine-3-aminoquinoline (MC-02,595) have been prepared and evaluated for their ability to potentiate the activity of the fluoroquinolone levofloxacin in Pseudomonas aeruginosa. A number of the new analogues were as active or more active than the lead, demonstrating that a peptide backbone is not essential for activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11858997     DOI: 10.1016/s0960-894x(02)00006-9

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  13 in total

1.  Structure-activity relationships of potentiators of the antibiotic activity of clarithromycin against Escherichia coli.

Authors:  Gifty Blankson; Ajit K Parhi; Malvika Kaul; Daniel S Pilch; Edmond J LaVoie
Journal:  Eur J Med Chem       Date:  2019-05-29       Impact factor: 6.514

2.  Advances in the structural studies of antibiotic potentiators against Escherichia coli.

Authors:  Gifty A Blankson; Ajit K Parhi; Malvika Kaul; Daniel S Pilch; Edmond J LaVoie
Journal:  Bioorg Med Chem       Date:  2019-06-04       Impact factor: 3.641

Review 3.  The hydrophobic trap-the Achilles heel of RND efflux pumps.

Authors:  Zachary Aron; Timothy J Opperman
Journal:  Res Microbiol       Date:  2017-11-13       Impact factor: 3.992

Review 4.  Optimization of a novel series of pyranopyridine RND efflux pump inhibitors.

Authors:  Zachary Aron; Timothy J Opperman
Journal:  Curr Opin Microbiol       Date:  2016-05-24       Impact factor: 7.934

Review 5.  Mycobacterium tuberculosis Major Facilitator Superfamily Transporters.

Authors:  Ping Li; Yinzhong Gu; Jiang Li; Longxiang Xie; Xue Li; Jianping Xie
Journal:  J Membr Biol       Date:  2017-08-29       Impact factor: 1.843

Review 6.  Fluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosis.

Authors:  Matthew Hurley; Alan Smyth
Journal:  Ther Adv Respir Dis       Date:  2012-09-11       Impact factor: 4.031

Review 7.  Efflux-mediated drug resistance in bacteria.

Authors:  Xian-Zhi Li; Hiroshi Nikaido
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Characterization of a novel pyranopyridine inhibitor of the AcrAB efflux pump of Escherichia coli.

Authors:  Timothy J Opperman; Steven M Kwasny; Hong-Suk Kim; Son T Nguyen; Chad Houseweart; Sanjay D'Souza; Graham C Walker; Norton P Peet; Hiroshi Nikaido; Terry L Bowlin
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

9.  Efflux pump inhibitors (EPIs) as new antimicrobial agents against Pseudomonas aeruginosa.

Authors:  Momen Askoura; Walid Mottawea; Turki Abujamel; Ibrahim Taher
Journal:  Libyan J Med       Date:  2011-05-13       Impact factor: 1.657

Review 10.  Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.

Authors:  Matthew N Hurley; Miguel Cámara; Alan R Smyth
Journal:  Eur Respir J       Date:  2012-06-27       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.